GlassScriptPhysician profile
Omar Tan Manlapaz
NPI 1730348426
$25,249.11
in general payments reported to CMS, 2019-2025
59 companies · $6,006 in 2025
The $6,006 reported for 2025 was more than what 88% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,592 · 2020: $888 · 2021: $2,017 · 2022: $3,634 · 2023: $3,905 · 2024: $5,206 · 2025: $6,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,075.15 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,610.42 | 2019-2025 | Freestyle Libre, Freestyle Libre 3, Eterna |
| Amgen INC. | $2,601.07 | 2019-2025 | Tepezza, Evenity, Prolia |
| Lilly USA, LLC | $2,381.30 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,748.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $1,317.26 | 2019-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,124.42 | 2019-2025 | Jardiance, Synjardy |
| Xeris Pharmaceuticals, INC. | $1,060.55 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $1,055.34 | 2019-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $1,030.29 | 2019-2025 | |
| Insulet Corporation | $899.26 | 2019-2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $780.68 | 2019-2025 | Farxiga |
| Tandem Diabetes Care, INC. | $707.92 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $664.09 | 2019-2025 | Afrezza |
| Bayer Healthcare Pharmaceuticals INC. | $575.78 | 2021-2025 | |
| Abbvie INC. | $535.81 | 2019-2025 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $406.18 | 2025 | Twiist |
| Medtronic, INC. | $357.93 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Merck Sharp & Dohme LLC | $335.68 | 2019-2023 | Steglatro, Januvia, Verquvo |
| Alexion Pharmaceuticals, INC. | $298.68 | 2019-2025 | Strensiq |
| Cequr Corporation | $289.25 | 2022-2025 | Cequr Simplicity |
| Zealand Pharma US, INC. | $281.94 | 2021-2022 | |
| Amarin Pharma, INC. | $272.05 | 2019-2023 | |
| Intuity Medical INC | $263.83 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $217.74 | 2019-2023 | Cycloset |
| Madrigal Pharmaceuticals | $200.60 | 2025 | Rezdiffra |
| Amryt Pharma Holdings LTD | $174.58 | 2023 | Mycapssa |
| Ibsa Pharma INC. | $170.30 | 2019-2024 | Tirosint, Licart, Tirosint |
| Ascendis Pharma Endocrinology INC | $168.27 | 2025 | Yorvipath |
| Horizon Therapeutics Plc | $129.97 | 2023 | Tepezza |
| Valeritas, INC. | $124.99 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $124.73 | 2024-2025 | |
| Grt US Holding, INC. | $124.66 | 2022 | |
| Pfizer INC. | $111.86 | 2019-2024 | |
| Beta Bionics, INC. | $111.53 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amneal Pharmaceuticals LLC | $98.46 | 2019-2025 | Unithroid |
| Radius Health, INC. | $95.62 | 2019-2024 | Tymlos |
| Recordati_rare_diseases_inc. | $60.76 | 2021-2024 | Signifor Lar, Isturisa |
| Aytu Biopharma, INC. | $55.20 | 2019-2020 | |
| Avvisto Therapeutics, LLC | $49.68 | 2024-2025 | Cycloset |
| Antares Pharma, INC. | $49.12 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $45.33 | 2019-2024 | Contrave |
| Medtronic Minimed, INC. | $43.98 | 2019-2020 | |
| Vifor Pharma, INC. | $43.71 | 2019 | |
| Janssen Pharmaceuticals, INC | $39.64 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $38.76 | 2020-2022 | |
| Kyowa Kirin, INC. | $38.11 | 2023-2024 | Crysvita |
| Companion Medical, INC. | $37.49 | 2019-2020 | |
| Shire North American Group INC | $37.35 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $36.21 | 2019-2021 | |
| Averitas Pharma INC. | $35.00 | 2025 | Qutenza |
| Lifescan, INC. | $30.55 | 2022 | |
| Gilead Sciences, INC. | $25.91 | 2019 | |
| Chiesi USA, INC. | $25.37 | 2024 | Mycapssa |
| Becton, Dickinson and Company | $24.49 | 2019 | |
| Esperion Therapeutics, INC. | $22.62 | 2024 | Nexletol |
| Nevro Corp. | $16.77 | 2024 | Senza |
| Novartis Pharmaceuticals Corporation | $14.14 | 2023 | |
| Eusa Pharma (US) LLC | $13.86 | 2022 | |
| Vistapharm, INC. | $13.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Manlapaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.